Clinical Trial Update: Single Agent Regorafenib in Refractory Advanced Biliary Cancers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating single-agent regorafenib in refractory advanced biliary cancers has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cancer of the Bile Duct

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Cancer of the Bile Duct | Phase 2 | Status: COMPLETED | Results posted: 2020-01-13